Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1521-1540 of 1,694 trials

Ulcerative Colitis: Tofacitinib's Impact on Blood Clotting

We are studying how tofacitinib affects blood clotting and platelet function in patients with ulcerative colitis. This trial also compares its effects to other treatments and collects samples for future research.

Ulcerative Colitis3-6 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyHematology

STOP-LEUKEMIA: Metformin for Blood Disorders

We are investigating whether metformin can help prevent leukemia in patients with clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes. This study will assess the safety of metformin and explore how it may affect disease progression.

Myelodysplastic Syndromes (MDS)Clonal Cytopenia of Undetermined Significance (CCUS)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Heart Failure: PF-07328948 Study

We are testing a new oral medication for adults with heart failure to see if it improves heart function and symptoms compared to a placebo. The study also examines the safety of this treatment.

Heart Failure6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

CBD for Alcohol Use Disorder: A Phase II Trial

We are studying whether adding cannabidiol to standard treatment helps patients with severe alcohol use disorder stay abstinent after inpatient care. The trial also looks at the safety of CBD and its effects on withdrawal and anxiety symptoms.

Alcohol Use Disorder≤3 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesInternal MedicinePsychiatry

Chronic Kidney Disease: Vicadrostat and Empagliflozin Study

We are investigating whether starting vicadrostat with empagliflozin helps people with chronic kidney disease. The study compares two different ways of starting the medications to see which is more effective.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteDiabetologyNephrology

Usher Syndrome Type 1B: AAVB-081 Injection Study

We are testing a new subretinal injection for patients with Usher Syndrome Type 1B to see if it is safe and how it affects retinal health. The goal is to find a dose that balances safety and effectiveness.

Usher Syndrome Type 1B>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Immune Thrombocytopenia: Pirtobrutinib Study

We are investigating a new medication, pirtobrutinib, for adults with immune thrombocytopenia. The study aims to assess its safety and effectiveness compared to a placebo.

Immune Thrombocytopenia≤3 monthsSafety phase (I)Efficacy phase (II)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteHematology

Glaucoma: Oral Semaglutide Study

We are investigating whether oral semaglutide can safely improve retinal function in patients with open-angle glaucoma. This research may help find new ways to protect vision in those affected by this condition.

Glaucoma>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementEndocrinologyOphthalmology

Myoclonic Astatic Epilepsy: Fenfluramine Safety Study

We are monitoring the long-term safety of Fenfluramine as an add-on therapy for patients with Myoclonic Astatic Epilepsy. This study aims to ensure the treatment is safe and effective for managing seizures.

Myoclonic-Astatic Epilepsy>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Metastatic Colorectal Cancer: Cetuximab Treatment Study

We are exploring a new treatment approach using cetuximab for patients with specific genetic markers in metastatic colorectal cancer. The study aims to understand its effectiveness, safety, and impact on quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Colonoscopy Prep: Comparing Plenvu® and Picoprep®

We are studying how well Plenvu® works compared to Picoprep® for cleaning the bowel before a colonoscopy. The goal is to see which option is more effective and easier for patients to tolerate.

Healthy Participants for Colonoscopy Preparation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterology

Turner Syndrome: Oral vs. Transdermal Estrogen

We are studying whether oral and transdermal estrogen treatments provide similar benefits for women with Turner Syndrome. This research may help tailor hormone therapy to individual needs.

Turner's Syndrome≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Alzheimer's Disease: NSC001 Medication Study

We are investigating the safety and tolerability of a new medication, NSC001, for people with mild to moderate Alzheimer's disease. This study will help us learn more about how the medication works in the body.

Alzheimer's Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurology

Ulcerative Rectal Colitis: Tofacitinib Response Study

We are researching what factors may predict how well patients with ulcerative rectal colitis respond to Tofacitinib therapy. This could help improve treatment strategies for better patient care.

Ulcerative Colitis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Mycobacterium Avium Complex Lung Infections: Comparing Antibiotics

We are studying whether azithromycin is as effective as clarithromycin for treating lung infections caused by Mycobacterium avium complex. The trial also examines safety and side effects of both treatments.

Mycobacterium Avium Complex Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Steroid Withdrawal in Systemic Lupus Erythematosus (SLE)

We are studying whether stopping glucocorticoids is as effective as continuing a low dose for patients with stable SLE. This research aims to understand the impact on disease activity and quality of life over three years.

Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineRheumatology

Lung Cancer Treatment: Telisotuzumab Adizutecan with Osimertinib

We are studying a new combination treatment for adults with advanced EGFR-mutated non-small cell lung cancer. The goal is to see if this approach is safer and more effective than current standard treatments.

Non-Small Cell Lung Cancer6-12 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Hydroxychloroquine for Mastocytosis Symptoms

We are studying whether hydroxychloroquine can help reduce itching and flushing in patients with isolated cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement. The trial also looks at other symptoms and how well patients tolerate the treatment.

Mastocytosis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesDermatologyInternal Medicine

Clostridioides difficile Infection: Shorter Vancomycin Treatment

We are studying whether a 5-day course of oral vancomycin is as effective as the standard 10-day treatment for Clostridioides difficile infection. This trial will also assess recovery rates and safety for participants.

Clostridioides difficile Infection6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesGastroenterologyInfectious Diseases

Nebivolol for High Blood Pressure in Teens

We are studying how well Nebivolol works to lower blood pressure in adolescents with hypertension. The trial will also look at the safety of this medication during treatment.

Juvenile Hypertension6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine